News

Clinical & Regulatory,Pharmaceuticals and therapeutics
FDA approves daraxonrasib for second-line pancreatic cancer
read more
Biotech & Pharma Business,Digital & Data
PharmaForceIQ launches AI platform for pharma commercial teams
read more
Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics
Biogen’s felzartamab approved in China for multiple myeloma
read more
Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
Agenus reports deep responses with immunotherapy in Phase 2 colon cancer study
read more
Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development
CEPI funds Minapharm’s Phase 1 Bundibugyo Ebola vaccine programme
read more
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
Sagimet prepares Phase 3 acne trial for first US patients
read more
Advanced Therapies,Drug Delivery & Formulation,Drug Discovery & Development,Research & Development
Circio and Full Circles Therapeutics combine technologies for in vivo cell therapy
read more
Biotech & Pharma Business,Manufacturing & Supply Chain,Research & Development
Piramal Pharma reports 22.6% emissions reduction and zero OAI observations in sustainability report
read more
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
FDA approves ViiV’s Tivicay PD for young children with HIV
read more
Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Manufacturing & Supply Chain,Research & Development
Centrix and University of Sussex launch £375,000 data science project for drug development
read more
Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Research & Development
How AI is reshaping clinical trials: Saama on the next phase of regulated AI
read more
Clinical & Regulatory,Medical devices,Research & Development,Therapeutic Areas
MRI study suggests some prostate cancer biopsies could eventually be avoided
read more
Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
START and Allegheny Health Network to expand access to early-phase cancer trials
read more
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Polaryx advances Phase 2 trial of PLX-200 in four rare diseases
read more
Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development
Lumen Bioscience gets up to $7M to advance LMN-1001 into Phase 1
read more
Advanced Therapies,Clinical & Regulatory,Digital & Data,Research & Development,Therapeutic Areas
Brainomix to present five ILD studies on quantitative CT at ERS Congress
read more

FDA approves daraxonrasib for second-line pancreatic cancer

PharmaForceIQ launches AI platform for pharma commercial teams

Biogen’s felzartamab approved in China for multiple myeloma

Agenus reports deep responses with immunotherapy in Phase 2 colon cancer study

CEPI funds Minapharm’s Phase 1 Bundibugyo Ebola vaccine programme

Sagimet prepares Phase 3 acne trial for first US patients

Circio and Full Circles Therapeutics combine technologies for in vivo cell therapy

Piramal Pharma reports 22.6% emissions reduction and zero OAI observations in sustainability report

FDA approves ViiV’s Tivicay PD for young children with HIV

Centrix and University of Sussex launch £375,000 data science project for drug development

How AI is reshaping clinical trials: Saama on the next phase of regulated AI

MRI study suggests some prostate cancer biopsies could eventually be avoided

START and Allegheny Health Network to expand access to early-phase cancer trials

Polaryx advances Phase 2 trial of PLX-200 in four rare diseases

Lumen Bioscience gets up to $7M to advance LMN-1001 into Phase 1

Brainomix to present five ILD studies on quantitative CT at ERS Congress

main menu

recent posts

MRI study suggests some prostate cancer biopsies could eventually be avoided

START and Allegheny Health Network to expand access to early-phase cancer trials

Polaryx advances Phase 2 trial of PLX-200 in four rare diseases

get connected